{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:00:30Z","timestamp":1790053230058,"version":"4.0.1"},"reference-count":59,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Higher-risk Myelodysplastic Syndromes\/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain the only disease-modifying therapies, and are palliative in nature. Recent interest has grown in extending combination chemotherapies used to treat acute myeloid leukemia (AML) to patients with MDS, including novel combination chemotherapy \u201cdoublets\u201d and \u201ctriplets.\u201d In this review, we discuss considerations around combination chemotherapy in MDS, specifically as relates to study design, appropriate endpoints, supportive considerations, and how to integrate these into the current treatment paradigm. New therapies in MDS are desperately needed but also require considerations particular to this unique patient population.<\/jats:p>","DOI":"10.46989\/001c.88301","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:59:41Z","timestamp":1699001981000},"source":"Crossref","is-referenced-by-count":3,"title":["Are We Ready For \u201cTriplet\u201d Therapy in Higher-Risk MDS?"],"prefix":"10.46989","volume":"5","author":[{"given":"Andrew M.","family":"Brunner","sequence":"first","affiliation":[{"name":"Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Leipzig University Hospital, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Centre at John Hopkins, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"30","key":"ref1","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/jco.20.02724","article-title":"Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)","volume":"39","author":"Nicolaus Kr\u00f6ger","year":"2021","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/jco.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Alice B. Kornblith","year":"2002","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.blre.2021.100851","article-title":"Targeting health-related quality of life in patients with myelodysplastic syndromes \u2013 Current knowledge and lessons to be learned","volume":"50","author":"Esther N. Oliva","year":"2021","journal-title":"Blood Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/0268-960X","issn-type":"print"},{"issue":"24","key":"ref4","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/jco.2011.35.8135","article-title":"Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure","volume":"29","author":"Thomas Pr\u00e9bet","year":"2011","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Elias J. Jabbour","year":"2015","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.3324\/haematol.2012.071050","article-title":"Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure","volume":"98","author":"T. Prebet","year":"2013","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","article-title":"A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival","volume":"104","author":"Jacqueline S. Garcia","year":"2021","journal-title":"Leukemia Research","ISSN":"https:\/\/id.crossref.org\/issn\/0145-2126","issn-type":"print"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): A large propensity score-matched population-based study","volume":"61","author":"Amy J. Davidoff","year":"2020","journal-title":"Leukemia &amp; Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13643-018-0805-7","article-title":"A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome","volume":"7","author":"Jehad Almasri","year":"2018","journal-title":"Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/2046-4053","issn-type":"print"},{"issue":"7","key":"ref10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Amer M. Zeidan","year":"2017","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Uwe Platzbecker","year":"2019","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"16_suppl","key":"ref12","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1200\/jco.2022.40.16_suppl.7017","article-title":"Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.","volume":"40","author":"David Andrew Sallman","year":"2022","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"Supplement 1","key":"ref13","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood-2022-158612","article-title":"Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)","volume":"140","author":"Amer M. Zeidan","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"Supplement 1","key":"ref14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2021-145613","article-title":"Molecular Responses Are Observed across Mutational Spectrum in Treatment-Na\u00efve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine","volume":"138","author":"Jacqueline S. Garcia","year":"2021","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/bloodadvances.2021006357","article-title":"Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly \u201cpromising\u201d?","volume":"6","author":"Andrew M. Brunner","year":"2022","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"6","key":"ref16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.v89.6.2079","article-title":"International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes","volume":"89","author":"Peter Greenberg","year":"1997","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/1528-0020","issn-type":"print"},{"issue":"12","key":"ref17","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Peter L. Greenberg","year":"2012","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"7","key":"ref18","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/evidoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Elsa Bernard","year":"2022","journal-title":"NEJM Evidence","ISSN":"https:\/\/id.crossref.org\/issn\/2766-5526","issn-type":"print"},{"issue":"11","key":"ref19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Daniel A. Arber","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"7","key":"ref20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Joseph D. Khoury","year":"2022","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"101072","DOI":"10.1016\/j.blre.2023.101072","article-title":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)","volume":"60","author":"Jan Philipp Bewersdorf","year":"2023","journal-title":"Blood Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/0268-960X","issn-type":"print"},{"issue":"1","key":"ref22","first-page":"56","article-title":"Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches","volume":"16","author":"Andrew M. Brunner","year":"2018","journal-title":"Clinical Advances in Hematology & Oncology: H&O","ISSN":"https:\/\/id.crossref.org\/issn\/1543-0790","issn-type":"print"},{"issue":"7","key":"ref23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Asmita Mishra","year":"2013","journal-title":"American journal of hematology","ISSN":"https:\/\/id.crossref.org\/issn\/0361-8609","issn-type":"print"},{"issue":"5","key":"ref24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"James W. Vardiman","year":"2009","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"12","key":"ref25","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","volume":"36","author":"Amer M. Zeidan","year":"2022","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"24","key":"ref26","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/jco.2015.66.2510","article-title":"Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Mikkael A. Sekeres","year":"2017","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"17","key":"ref27","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Lionel Ad\u00e8s","year":"2022","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.18193","article-title":"A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM\u2019s \u201cpick a winner\u201d trial, with the impact of somatic mutations","volume":"198","author":"Lionel Ad\u00e8s","year":"2022","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"14","key":"ref29","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/jco.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in <i>TP53<\/i>-Mutant Myelodysplastic Syndromes","volume":"39","author":"David A. Sallman","year":"2021","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"7","key":"ref30","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Mikkael A. Sekeres","year":"2021","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Amer M. Zeidan","year":"2023","journal-title":"American Journal of Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/0361-8609","issn-type":"print"},{"issue":"7","key":"ref32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"Courtney D. DiNardo","year":"2020","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/hematology.2021000277","article-title":"Lower risk but high risk","volume":"2021","author":"Amy E. DeZern","year":"2021","journal-title":"Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/1520-4391","issn-type":"print"},{"issue":"10","key":"ref34","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1016\/s2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Alexandre Bazinet","year":"2022","journal-title":"The Lancet Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/2352-3026","issn-type":"print"},{"issue":"11","key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00744-z","article-title":"Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome","volume":"12","author":"Rami S. Komrokji","year":"2022","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"5","key":"ref36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/10428194.2016.1228927","article-title":"Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings","volume":"58","author":"Brian Ball","year":"2017","journal-title":"Leukemia &amp; Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"issue":"2","key":"ref37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Abhishek Maiti","year":"2021","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"9","key":"ref38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"S. Vincent Rajkumar","year":"2020","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"39","key":"ref39","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1200\/edbk_238527","article-title":"Induction Therapy for Newly Diagnosed Multiple Myeloma","author":"Barry Paul","year":"2019","journal-title":"American Society of Clinical Oncology Educational Book","ISSN":"https:\/\/id.crossref.org\/issn\/1548-8748","issn-type":"print"},{"issue":"10","key":"ref40","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1038\/bcj.2016.89","article-title":"The role of maintenance therapy in multiple myeloma","volume":"6","author":"B Lipe","year":"2016","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"Suppl 1","key":"ref41","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/s2152-2650(20)30448-1","article-title":"Pitfalls in Assessing Response to Treatment in MDS","volume":"20","author":"Uwe Platzbecker","year":"2020","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"14","key":"ref42","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1158\/1078-0432.ccr-22-3348","article-title":"Considerations for Drug Development in Myelodysplastic Syndromes","volume":"29","author":"Mikkael A. Sekeres","year":"2023","journal-title":"Clinical Cancer Research","ISSN":"https:\/\/id.crossref.org\/issn\/1078-0432","issn-type":"print"},{"issue":"Supplement 1","key":"ref43","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2021-147558","article-title":"Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses","volume":"138","author":"Nina Kim","year":"2021","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"12","key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00765-8","article-title":"Management of patients with lower-risk myelodysplastic syndromes","volume":"12","author":"Andrew M. Brunner","year":"2022","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"5","key":"ref45","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/bjh.17838","article-title":"Meaningful response criteria for myelodysplastic syndromes","volume":"196","author":"Nina Kim","year":"2022","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"11","key":"ref46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41408-022-00748-9","article-title":"Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)","volume":"12","author":"Andrew M. Brunner","year":"2022","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"blood.2022018604","DOI":"10.1182\/blood.2022018604","article-title":"Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes","author":"Amer M. Zeidan","year":"2023","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"3","key":"ref48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41375-019-0704-5","article-title":"Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?","volume":"34","author":"Elihu Estey","year":"2020","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"1","key":"ref49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1745-6215-10-27","article-title":"Design, analysis, and presentation of crossover trials","volume":"10","author":"Edward J Mills","year":"2009","journal-title":"Trials","ISSN":"https:\/\/id.crossref.org\/issn\/1745-6215","issn-type":"print"},{"issue":"2","key":"ref50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/moh.0000000000000749","article-title":"Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia","volume":"30","author":"Andrew M. Brunner","year":"2023","journal-title":"Current Opinion in Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/1065-6251","issn-type":"print"},{"issue":"6","key":"ref51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.15273","article-title":"Azacitidine in the \u2018real-world\u2019: an evaluation of 1101 higher-risk myelodysplastic syndrome\/low blast count acute myeloid leukaemia patients in Ontario, Canada","volume":"181","author":"Lee Mozessohn","year":"2018","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"36","key":"ref52","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?","volume":"17","author":"Amer M Zeidan","year":"2021","journal-title":"Future Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1479-6694","issn-type":"print"},{"issue":"2","key":"ref53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/10428194.2019.1663423","article-title":"Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents","volume":"61","author":"Amer M. Zeidan","year":"2020","journal-title":"Leukemia &amp; Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"issue":"6","key":"ref54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Guillermo Garcia-Manero","year":"2020","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"ref55","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current challenges and unmet medical needs in myelodysplastic syndromes","volume":"35","author":"Uwe Platzbecker","year":"2021","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"12","key":"ref56","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.clml.2022.07.012","article-title":"SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes","volume":"22","author":"Brandon J. Aubrey","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"3","key":"ref57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Pierre Fenaux","year":"2009","journal-title":"The lancet oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"issue":"23","key":"ref58","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1200\/jco.2008.19.6550","article-title":"Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial","volume":"27","author":"David P. Steensma","year":"2009","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"30","key":"ref59","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/jco.20.03380","article-title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome","volume":"39","author":"Ryotaro Nakamura","year":"2021","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/88301-are-we-ready-for-triplet-therapy-in-higher-risk-mds","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:04:07Z","timestamp":1739304247000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/88301-are-we-ready-for-triplet-therapy-in-higher-risk-mds"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.88301","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}